Skip to main content

and
  1. Article

    Open Access

    Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial

    Low-dose tamoxifen halves recurrence in non-invasive breast cancer without significant adverse events. Some adjuvant trials with tamoxifen 20 mg/day had shown an association between low endoxifen levels (9–16 ...

    Andrea DeCensi, Harriet Johansson, Thomas Helland, Matteo Puntoni in npj Breast Cancer (2021)

  2. Article

    Open Access

    Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation

    In a 3-arm presurgical trial, four-six weeks exemestane 25 mg three times/week (TIW) was non-inferior to 25 mg/day (QD) in suppressing circulating estradiol in postmenopausal women with ER-positive breast canc...

    Harriet Johansson, Aliana Guerrieri-Gonzaga, Sara Gandini in npj Breast Cancer (2024)